Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing with an epidemic growth rate. Animal studies with taurine supplementation have shown increased insulin secretion and action, suggesting that taurine supplementation may have a potential to prevent T2DM. Objective: To assess the effect of taurine treatment on insulin secretion and action, and on plasma lipid levels in overweight men with a positive history of T2DM. Design: 20 nondiabetic subjects were included in a double-blinded, randomized, crossover study, receiving a daily supplementation of 1.5 g taurine or placebo for two periods of 8 weeks. The subjects were overweight first-degree relatives of T2DM patients. An intravenous glucose tolerance test (IVGTT) was used to measure first-phase insulin secretory response, and a euglycemic hyperinsulinemic clamp was used to determine peripheral insulin action. Results: Mean plasma taurine concentration was 3977 (s.d.) mmol/l after placebo and 131762 mmol/l after taurine intervention (Po0.0001). There was no significant difference after taurine intervention compared to placebo in incremental insulin response (Ins incr. ) neither during the IVGTT, nor in insulin-stimulated glucose disposal during the clamp. Insulin secretion, adjusted for insulin sensitivity, was also unchanged. There was no significant effect of taurine supplementation on blood lipid levels as well. Conclusion: Daily supplementation with 1.5 g taurine for 8 weeks had no effect on insulin secretion or sensitivity, or on blood lipid levels. These findings in persons with an increased risk of T2DM are in contrast to those from animal studies, and do not support the assumption that dietary supplementation with taurine can be used to prevent the development of T2DM.
Introduction
The prevalence of type II diabetes mellitus (T2DM) is increasing, with the most dramatic increase expected to occur in the developing countries (King et al, 1998) . T2DM is a heterogeneous metabolic disorder characterized by both defective pancreatic insulin secretion and insulin resistance (Beck-Nielsen & Groop, 1994) . Early stages of T2DM are often present several years prior to the time of diagnosis. T2DM is associated with an increased morbidity and mortality due to the development of micro-and macrovascular complications (DeFronzo & Ferrannini, 1991; BeckNielsen et al, 2000) . Unfortunately, effective and sustainable prevention programs are limited, and treatment options for T2DM are restricted (Harris, 1998; Tuomilehto et al, 2001 ).
Both genetic and environmental factors are involved in the etiology of T2DM. The lifetime risk of developing T2DM among nondiabetic first-degree relatives of type II diabetic patients compared with controls without a family history of diabetes averages about 40% (Köbberling & Tillil, 1982; Haas et al, 1994) . Environmental factors such as obesity and low physical activity level are of particular importance (DeFronzo & Ferrannini, 1991) as well as low birth weight indicating intrauterine malnutrition (Hales & Barker, 1992) .
Taurine is a sulfur-containing amino acid that is synthesized in limited amounts from cysteine and methionine, but is also present in the diet. Taurine has many metabolic as well as nonmetabolic functions (Kulakowski & Maturo, 1984; Hansen, 2001 ). Taurine metabolism is regulated primarily by excretion via the urine, while only a small part is excreted as bile salts (Sturman et al, 1975) .
The average daily taurine intake in man is between 80 and 225 mg, originating mainly from products of animal origin (Laidlaw et al, 1988) . Currently, there are no official recommendations for daily taurine intake (Laidlaw et al, 1988; Hayes & Sturman, 1981) . More documentation of taurine's potential nutritional role and knowledge about its biological function in humans is needed.
Several animal studies have indicated that taurine supplementation improve insulin sensitivity (Anuradha & Balakrishnan, 1999; . Anuradha and Balakrishnan (1999) found that adding taurine (2%) to the ad libitum drinking water of fructose-fed Wistar rats decreased the fructose-induced exaggerated glucose levels and hyperinsulinemia (Po0.05). The same observations were made by Nakaya et al (2000) when 5% taurine was added to the food of fructose-fed Otsuka Long Evans Tokushima Falty (OLETF) diabetic rats, resulting in less hyperglycemia and decreased insulin resistance. In a recent study by with fructose-fed insulin-resistant rats, an IVGTT showed an enhanced insulin action when a dose of taurine 2% w/w was added to drinking water.
The possible effect of taurine on insulin sensitivity and secretion in humans has not yet been investigated. A few clinical trials with taurine supplementation in diabetic patients have been reported. In a study of diabetic patients, Elizarova and Nedosugova (1996) found a decrease in the average daily glucose levels when 0.5 g of taurine was orally supplemented twice a day for 30 days, suggesting a glucoselowering effect of taurine. Furthermore, studies have shown that both type I and II diabetic patients have a reduced plasma taurine concentration compared to healthy control subjects (Franconi et al, 1995; De Luca et al, 2001a) . In the study by Franconi et al (1995) , the plasma taurine levels increased to slightly above the level of the control group, when a supplement of 1.5 g taurine per day for 90 days was given. Animal studies show that taurine also seems to have a lipid-lowering effect (Murakami et al, 1999 (Murakami et al, , 2000 (Murakami et al, , 2002 .
We consequently investigated the metabolic effects of taurine on glucose and fat metabolism in healthy subjects with a high risk of developing T2DM. The above-mentioned subjects were chosen since treatment modalities for type II diabetes are often inadequate, or it has become too late to prevent diabetic complications. Therefore, preventive actions are preferable.
Subjects and methods

Subjects
A total of 20 men aged 35-65 years were recruited through the patient register at Steno Diabetes Center or through local newspaper advertisements. Study inclusion criteria included a family history of T2DM in at least one first-degree relative, a body mass index (BMI) greater than 25 kg/m 2 , and a low physical activity level. The study participants had to be in good general health, and were not allowed to take any medication that could affect the outcome of the study. The participants had to be nondiabetic, that is have normal or impaired glucose tolerance (IGT) according to WHO's values for diagnosis of diabetes mellitus and other categories of hyperglycaemia (Alberti & Zimmet, 1998) . All subjects were screened using a standard oral glucose tolerance test (OGTT).
Five of the included subjects had IGT. The study protocol was in accordance with the Helsinki Declaration II, and approved by The Danish Research Agency (KA 01122 g) and The Danish Data Protection Agency (J.nr. 2001-41-1531) . All subjects signed an informed consent form before entering the study.
Study design
The study was designed as a randomized, double-blinded, crossover intervention, and was carried out as shown in Figure 1 . Eligible participants were randomly assigned to either 8 weeks of taurine or placebo (cellulose) intervention during the first period, followed by a 2-week wash-out period. The participants would thereafter begin the second 8-week period and receive the opposite intervention of the first period ( Figure 1 ). Taurine was administered in capsules, with a daily dose of 1.5 g divided into two capsules of each 0.75 g, which had to be taken in the morning and evening. A person independent of the study kept the randomization code and distributed the capsules to the participants. None of the study-personnel had access to either the capsules or the code during the trial. The study consisted of five visits, including an OGTT screen visit. After the first 8-week period, the participants underwent a meal-test to determine postprandial fat metabolism, and a euglycemic hyperinsulinemic clamp to determine glucose metabolism including insulin secretion, insulin sensitivity and substrate oxidation. The two examinations were placed on separate days preferably within the same week, and were repeated after the second 8-week period. Subjects were asked to follow a standardized diet and lifestyle for 3 days prior to the examinations.
Methods
OGTT.
After a 10-h overnight fast, the subjects were given a standard 75 g oral glucose load. Venous blood samples were taken before and 30, 60 and 120 min after glucose intake.
Meal-test. After a 10-h overnight fast, the subjects were given a standardized high-fat breakfast with an energy distribution of 37 E% carbohydrate, 51 E% fat and 12 E% protein. The meal had to be eaten within 15 min. Venous blood samples were obtained before and at 30, 60, 120, 240 and 360 min after breakfast to determine plasma glucose, insulin, C-peptide, free fatty acids (FFA) and triglyceride (TG) concentrations.
The Ins incr. from 0 to 30 min was calculated for the mealtest (Ins incr. Euglycemic hyperinsulinemic clamp. Examinations were started at 07.30 h after a 10-h overnight fast. A polyethylene catheter was inserted into an antecubital vein for blood sampling, and the hand was placed in a heated Plexiglas box to obtain arterialized venous blood. Another polyethylene catheter was inserted into an antecubital vein of the contralateral arm for infusion of test substances. Plasma for taurine concentration and full blood for HbA 1C analysis were drawn at baseline. During the basal period (0-40 min) blood was drawn for measuring plasma glucose, insulin, C-peptide, urea, FFA and TG concentrations.
After the basal period and the IVGTT (see below), a squared priming was performed (0-9 min) with a stepwise decline in the insulin (Actrapid s ; Novo Nordisk, Bagsvaerd, Denmark) infusion rate every third minute, thereby reducing the insulin infusion rate from 100 to 80 to 60 and finally to 40 Um/m 2 /min. Thereafter the insulin infusion rate was fixed at 40 Um/m 2 /min. The plasma glucose concentration was held constant at 5 mmol/l by variable glucose infusion using a negative feedback principle. As the rate of glucose metabolism can be determined at 5-min intervals, the time course of change in tissue insulin sensitivity can be followed (DeFronzo et al, 1979; Matthews et al, 1985) . Blood samples were drawn for insulin, C-peptide, FFA, TG and urea determination during the steady-state periods.
The total insulin-stimulated glucose disposal rate (Mvalue) was calculated as the mean glucose infusion rate during the last 30 min of the steady-state period, and was expressed as mg glucose/kg FFM/min. S I was calculated as the M-value/Ins 0-30 min . The D I-Clamp was calculated as S I Â AUC insulin,IVGTT (0-10 min) .
An IVGTT was performed to determine the first-phase insulin response (FPIR). A glucose (20%) bolus (0.3 g/kg body weight) was infused intravenously over 1 min whereafter venous blood was drawn for the determination of plasma glucose, insulin and C-peptide concentrations.
The FPIR was defined as the incremental area under the insulin curve during the first 10 min after initiation of the IV glucose bolus. The area under the curve (AUC) was defined as the total area under the glucose, insulin and C-peptide curves (0-10 min), respectively. The Ins incr.IVGTT was calculated as (Ins 30 ÀIns 0 ) Â 10 À9 /(Glu 30 ÀGlu 0 ). Homeostasis model assessment insulin resistance (HOMA-IR) was calculated as fasting plasma insulin (pmol/l) Â fasting plasma glucose (mmol/l)/22.5 (Matthews et al, 1985) .
Indirect calorimetry was performed to determine substrate utilization and basal metabolic rate (BMR) during the basal and insulin-stimulated steady-state periods, using a computerized flow-through canopy gas analyser system (Deltatract II Metabolic Monitor; Datex, Helsinki, Finland) with a ventilated hood. The ventilated hood was placed over the participant's head, and continuous gas exchange was determined. Oxygen consumption and carbon dioxide production was recorded and calculated each minute (Frayn, 1983; Ferrannini, 1988) . The calorimeter was cleared and restarted after the first 10 min to make sure that the subject was well adapted to the hood, and breathing was stable. Basal and insulin-stimulated glucose and lipid oxidation rates were calculated from the indirect calorimetry data, using the equations by Frayn (1983) . 
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The nonoxidative glucose metabolism was calculated for the insulin-stimulated period as the difference between the M-value and the rate of glucose oxidation determined by indirect calorimetry (M-valueÀglucose oxi. ins.stim. ).
Blood chemistry
Plasma glucose concentrations were determined using a Lifescan One Toucht blood glucose meter (Johnson & Johnson Company, Milpitas, CA, USA). Plasma insulin and C-peptide concentrations were determined by AutoDELPHIAt time-resolved fluroimmunoassay (Perkin Elmer-Wallac Oy, Turku, Finland). Serum FFA was quantified by an in vitro enzymatic colorimetric method (Wako, VA, USA), and HbA 1C was measured by high-performance liquid chromatography (HPLC) on a Bio Rad, Variantt (Bio-Rad Laboratories, CA, USA). The plasma amino-acid profile was measured by HPLC using norleucine as internal standard (Hubbard et al, 1988) .
Dietary recording
All participants had to complete a 4-day 24-h weighed food diary at the beginning of the study, and again at the end of the study. Energy intake and dietary analysis were conducted using a computerized program, Dankost 2000 (Danish Catering Service, Herlev, Denmark). The data were used mainly to ensure that participants did not change dietary intake during the study and thereby a measure of compliance. Average dietary taurine intake was also estimated based on the dietary records.
Statistics
Data were analyzed using SAS s (version 8.2; SAS Institute Inc., Cary, NC, USA). Comparison of data was done using two-way nonparametric methods. Wilcoxon's test was used for paired data. General linear model (GLM) was used for unbalanced data and ANOVA for balanced data. Clamp data were analyzed as repeated measurements during the steadystate period. Specific data for the clamp and meal-test were analyzed for nonparametric correlation by Spearman's rho (R). A post hoc power calculation was performed using the R Project for Statistical Computing. The crossover design, a population of 18, a standard deviation of 2.56, a level of significance of 0.05 and an acceptable power of 80% resulted in a delta value of 1.79. In other words, with this design including 18 subjects, there was an 80% chance (power) to detect a difference of 20% in the M-value between taurine and placebo treatment.
All data are presented as mean7s.d. In cases where data have extreme outliers, and therefore are not normally distributed, they are presented as the median with a range and are marked with an asterisk. Pp0.05 was considered significant in a two-tailed analysis, and PX0.05 was considered nonsignificant different marked with NS.
Results
Basal and IVGTT period A total of 18 subjects completed the study: two subjects were lost due to lack of compliance. The baseline (OGTT) clinical characteristics of the 18 subjects are shown in Table 1 . The mean LDL and total cholesterol values were elevated. All other values were within normal limits. Five subjects had a venous blood glucose concentration X6.7 mmol/l 2 h after the glucose load, indicating IGT according to the WHO criteria (Alberti & Zimmet, 1998) .
There were no significant differences in the clinical and biochemical characteristics measured on the clamp-day of the two intervention periods (Table 2) , except for the plasma taurine concentration, which was significantly greater after taurine intervention (Figure 2) . The general amino-acid profile did not change significantly (data not shown). Table 3 shows that there were no significant differences during the basal period between the placebo and taurine intervention for fasting plasma glucose, insulin, C-peptide, TG and FFA concentrations. There was no difference in HOMA-IR and Ins incr.-IVGTT for the two intervention periods as well.
No significant difference after taurine intervention was found in the AUC for plasma glucose, insulin or C-peptide concentration during the meal-test (Table 3 ). The lipidprofile did not change significantly either, and there was no difference in Ins incr.-Meal-test between the placebo and taurine intervention periods (data not shown).
Euglycemic hyperinsulinemic clamp. Table 4 shows that there were no significant differences in plasma glucose, insulin and C-peptide concentrations between the two Effect of taurine treatment on insulin secretion and action C Brøns et al interventions during the steady-state periods, and the difference between the placebo and taurine intervention period in the M-value was non-significant. Furthermore, no significant difference was found in S I between placebo and taurine. D I describes the insulin secretion after infusion of the glucose bolus, adjusted for the insulin sensitivity, and there was no significant difference between placebo and taurine (Table 4) either for the D I-Clamp (Figure 3) or for the D I-Meal-test (Figure 4) . The correlation between HOMA-IR OGTT and HOMA-IR on the day of the clamp (Table 5) showed a very good reproducibility of the HOMA-IR calculation.
Indirect calorimetry. There was no difference between the two periods in the basal and insulin-stimulated glucose and lipid oxidation rates or in the BMR. No difference was observed in the non-oxidative metabolism as well (Table 6 ).
Dietary intake. The results of the 4-day 24-h weighed food diary showed no significant difference in the average total energy intake and macronutrient distribution before and after the trial. There was no difference in the average habitual dietary taurine intake before and after the trial, which was estimated from the dietary records to be 199764 and 199775 mg/day, respectively.
Discussion
The participants of the current study had a first-degree relative with T2DM making them genetically predisposed to the disease. Furthermore, they had several nongenetic factors predisposing to T2DM, including overweight and physical inactivity, and consequently a substantial risk exceeding 40% of developing type II diabetes (Köbberling & Tillil, 1982; Haas et al, 1994) . The clinical characteristics of the subjects (Table 2) suggest that the lifestyle factors were not changed significantly during the intervention period. 
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We obtained a three-fold increase in plasma taurine concentration, after taurine intervention from a relatively narrow plasma taurine concentration range after placebo intervention (Table 2, Figure 2 ). The participants reported no indications of side effects or symptoms of toxicity with the current dose of taurine. Normal subjects have an average plasma taurine concentration in the range of 40-95 mmol/l (measured by HPLC) (De Luca et al, 2001a) . De Luca et al (2001b) reported a 34% reduced plasma taurine concentration (measured by HPLC) in diabetic patients (32.171.9 mmol/l) compared to healthy controls (48.674.9 mmol/l). Recognizing that no reference interval for plasma taurine concentration exists, it could be suggested that the participants of the current study, with regard to plasma taurine concentration (38.9 mmol/l), were in between the values found in overt diabetic patients and healthy controls corresponding with their status as being high-risk subjects. However, normal control subjects without predisposition to T2DM were not included in this study. Therefore, it is not known whether the subjects of the current study had reduced plasma taurine concentrations.
A pilot study could have been used to determine the length of the wash-out period. However, in the current study, the length of the wash-out period was determined based on findings by Sturman et al (1975) indicating that the largest taurine pool of approximately 98 mmol has a turnover rate of t 1/2 ¼ 70 h. The plasma taurine concentration could have been measured after the wash-out period in order to assure a sufficient wash-out. Nevertheless, the plasma taurine concentration range after placebo intervention was relatively narrow (Table 2, Figure 2) , indicating an acceptable length of the wash-out period.
A great variation in the increase in plasma taurine concentration after taurine administration was observed, and in some participants the plasma taurine concentration Effect of taurine treatment on insulin secretion and action C Brøns et al increased only marginally after the intervention (Figure 2 ). This could be due to lack of compliance, but could also be caused by a variation in the rates of taurine absorption, or perhaps in the metabolic clearance of taurine, that is excretion of taurine in urine and feces, which was not measured in the current study. Sturman et al (1975) found a nearly quantitative complete recovery of supplemental taurine in the urine, which suggests that the body taurine pools cannot be expanded greatly by exogenous taurine. The estimated dietary taurine intake (B200 mg/day) was relatively high in comparison with some other ethnic groups (Rana & Sanders, 1986; Zhao et al, 1998) . However, the dietary taurine intake was low compared to the supplementation dose of 1.5 g/day (Kibayashi et al, 2000) . An increased conjugation of bile acids with taurine results in an elevated excretion of cholesterol, suggesting a potential hypocholesterolemic effect of taurine (Cherif et al, 1998) . In the present study, there was no effect of taurine on the serum lipids, both when measured in the fasting state, during the euglycemic hyperinsulinemic clamp, or during the meal-test after intake of a high-fat breakfast. This is in contrast to the changes in LDL, HDL, total cholesterol and triglycerides after taurine supplementation, found by several investigators in animal studies (Cherif et al, 1998; Murakami et al, 1999 Murakami et al, , 2000 Murakami et al, , 2002 . One potential reason why this effect was not observed in the present study could be that the bile salts in humans are reabsorbed more efficiently.
We used two estimates-both IV and oral glucose stimulito determine if taurine had an effect on the Ins incr. (0-30 min) . No effect of taurine treatment was found on the FPIR after IV infusion of the glucose bolus, or on glucose levels after food intake (Table 3 ). There was a positive correlation between Ins incr.-Meal-test and Ins incr.-IVGTT . The correlation between the two methods was however not good, suggesting that the meal-test may not be a precise method for measuring b-cell function compared to the IVGTT (Table 5 ). The reason might be the influence of digestive factors, for example the possible interference of gut incretin hormones Glucagon like peptide 1 (GLP-1) and Gastric inhibitory polypeptide (GIP) which are glucosedependent insulinotropic peptides that enhance anabolism through their stimulation of insulin secretion in response to meals. Another reason could be that the breakfast, served on the day of the meal-test, had a high fat E% (B50 E%), which is known to delay gastric emptying (Stenson, 1998) . In turn, this could result in a postponed postprandial peak of the plasma insulin concentration.
The FPIR of the IVGTT was used to determine b-cell function as it is a simple method that reflects the acute insulin response, and can be related to insulin sensitivity (Granner & O'Brien, 1992) . The euglycemic hyperinsulinemic clamp technique is considered to be 'the gold standard' in vivo method to quantify tissue sensitivity to insulin with a high reproducibility (DeFronzo et al, 1979; Matthews et al, 1985) . The method allows for examination of the glucose metabolism during high physiological insulin levels, resembling the postprandial insulin levels under standardized conditions.
The correlation between HOMA-IR OGTT and S I for placebo and taurine was surprisingly good (Table 5) . It is well accepted that HOMA-IR provides a less valid measure of insulin resistance than the euglycemic hyperinsulinemic clamp technique (DeFronzo et al, 1979) . However, in the present study the two methods gave the same results, both demonstrating no effect of taurine on insulin sensitivity.
In order to determine if taurine had an effect on insulinstimulated glucose disposal in any possible insulin resistant subgroup, the M-value was analyzed separately for subjects with BMI429 kg/m 2 and IGT. In addition, the M-value was also analyzed for subjects with plasma taurine concentrations greater than the mean concentration after supplementation. Nevertheless, no effect of taurine was found on the M-value in any of these subgroups. Elizarova and Nedosugova (Elizarova & Nedosugova, 1996) found that a taurine supplement of 0.5 g twice a day for 30 days resulted in a significant decrease in the average blood glucose concentration in diabetic patients. We cannot Effect of taurine treatment on insulin secretion and action C Brøns et al exclude the possibility that this effect could have been found in the present study as well if diabetic subjects had been included. Several animal studies have shown that taurine has a beneficial effect on insulin sensitivity (Maturo & Kulakowski, 1988; Anuradha & Balakrishnan, 1999; Nakaya et al, 2000; . Human studies of type I and II diabetics have suggested that taurine has a glucose-lowering effect (Elizarova & Nedosugova, 1996; Franconi et al, 1996) . These studies were however not randomized or blinded. Furthermore, the study by Elizarova and Nedosugova (1996) had no control group, and included only 10 subjects. The results from the present well-controlled study are strongly in support of a lack of effect of taurine on glucose homeostasis. The M-value found in the current study corresponds well with the M-value (9.2 mg glucose/kg FFM/min) for relatives found in a previous study by Vaag et al (1992) , which was decreased compared to controls (Vaag et al, 1992) . The decrease was due to a reduction in nonoxidative glucose metabolism (Vaag et al, 1992) . This indicates that the study participants have a lower insulin-stimulated glucose disposal than healthy controls, and that they therefore did not benefit from any enhancing effect of taurine treatment on insulin action.
No changes in the relationship between oxidative and nonoxidative glucose metabolism were observed after taurine supplementation. This suggests that taurine does not have any effect on the intracellular metabolism or on partitioning of the intracellular glucose fluxes.
Intervention programs based on lifestyle intervention seem to be a preferential way of preventing type II diabetes since the increased prevalence and incidence of the disease is mainly due to responses to a sedentary lifestyle and excessive food intake. Recent comprehensive intervention studies have shown that type II diabetes can be prevented by changes in lifestyles of high-risk subjects. These lifestyle changes included low-fat, high fiber, less-calorie diets, and increased physical activity resulting in weight loss (Pan et al, 1997; Tuomilehto et al, 2001; Diabetes-Prevention PRG, 2002) . The study by showed that the risk of developing type II diabetes could be reduced by 31% with traditional metformin treatment, but by as much as 58% with lifestyle intervention. This suggests that dietary prevention is clinically relevant and more efficient than pharmacological prevention (Pan et al, 1997 ).
In the current study, a 20% difference in insulin-stimulated glucose disposal between placebo and taurine could have been detected with an 80% power. A 20% difference would be considered clinically relevant, since studies have found a significant increase between 20 and 25% in the insulin-stimulated glucose disposal, when both IGT and T2DM subjects are treated with metformin compared to placebo (Widen et al, 1992; Lehtovirta et al, 2001) . Taken together, it is unlikely that any clinical significant effect of taurine treatment on insulin action have been missed in this study.
In conclusion, oral supplementation with a dose of 1.5 g of taurine per day for 8 weeks had no effect on the insulin secretion or insulin sensitivity in overweight insulin-resistant relatives to type II diabetics. A lipid-lowering effect was not seen either. Animal studies indicated that taurine supplementation could represent an alternative tool to prevent diabetes by an improvement of insulin action. Our study does not support that this occurs for prediabetic humans.
